You are not logged in. FreshNews.com enhanced features available with FREE registration!

BiotechnologyCalif.CaliforniaData ManagementGeneral HealthHealthInc.LANCASTER
background image

Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share

Posted: October 28, 2015 12:55 pm (UTC)

Simulations Plus announced today that its board of directors has declared a cash dividend of $0.05 per share, to be distributed on November 16, 2015, for shareholders of record as of November 9, 2015.

Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share

LANCASTER, Calif. — (BUSINESS WIRE) —

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Monday, November 16, 2015, for shareholders of record as of Monday, November 9, 2015.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “This dividend declaration is a continuation of the Board’s plan to distribute a cash dividend of $0.05 per share per quarter. Of course, the board always has the discretion of discontinuing, increasing, or decreasing the dividend in accordance with the cash needs of the business.”

Mr. John Kneisel, chief financial officer of Simulations Plus, added: “Consolidated cash is about $8.6 million, consolidated accounts receivable is about $2.9 million, and consolidated accounts payable is about $121,000. This dividend distribution will use about $849,000.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. For more information, visit our website at www.simulations-plus.com.

Tags: , , , , , , , , , , , , ,

Category: